Triple Hair’s Feature in Le Journal de Montréal

MEDIA

Triple Hair is one of two startups mentioned in the latest Le Journal de Montréal article. Thank you for highlighting our achievements.

Read the full article here: https://www.journaldemontreal.com/2024/06/08/dans-lil-du-quebec-inc-des-patrons-de-cae-empochent

About Triple Hair

Triple Hair Group Inc. is a Canadian biotechnology company focused on the development of innovative therapies for androgenic alopecia, a condition affecting hundreds of millions of men and women worldwide.

The global hair-loss treatment market was valued at approximately US$8.8 billion in 2023 and is projected to reach over US$16 billion by 2030, reflecting the significant demand for safe and effective treatment options.

Triple Hair’s lead product candidate, TH07, is a patented prescription topical therapy currently in Phase III clinical development.

For more information, visit the Company’s website, at www.triplehair.ca/investors.

Contact:
Triple Hair Group
Jean-Philippe Gravel
President and CEO
investors@triplehair.ca

Triple Hair Expands Global Phase III Program for TH07 with Launch of…
Corporate

Triple Hair Expands Global Phase III Program for TH07 with Launch of…

Triple Hair Doses First Patient in Phase III Clinical Trial in Canada…
Corporate

Triple Hair Doses First Patient in Phase III Clinical Trial in Canada…

Triple Hair’s Feature in the NY Post
Media

Triple Hair’s Feature in the NY Post